

Padraig R Warde

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4424055/publications.pdf>

Version: 2024-02-01

256
papers

18,760
citations

17776

65
h-index

14779

131
g-index

266
all docs

266
docs citations

266
times ranked

12629
citing authors

#	ARTICLE	IF	CITATIONS
1	Management of stage I testicular cancer. <i>Current Opinion in Urology</i> , 2022, 32, 17-23.	0.9	4
2	Economic Evaluation of a Geriatric Oncology Clinic. <i>Cancers</i> , 2022, 14, 789.	1.7	10
3	Daily symptom monitoring commonly leads to treatment modification in older adults receiving treatment for metastatic prostate cancer (mPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 82-82.	0.8	1
4	Dosimetric comparison of MR-guided adaptive IMRT versus 3DOF-VMAT for prostate stereotactic radiotherapy. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2022, 21, 64-70.	0.6	0
5	Delivery of Cancer Care in Ontario, Canada, During the First Year of the COVID-19 Pandemic. <i>JAMA Network Open</i> , 2022, 5, e228855.	2.8	38
6	Safety of Minimizing Intensity of Follow-up on Active Surveillance for Clinical Stage I Testicular Germ Cell Tumors. <i>European Urology Open Science</i> , 2022, 40, 46-53.	0.2	6
7	Remote symptom monitoring (RSM) during treatment for metastatic prostate cancer (mPC) in older men: Feasibility and efficacy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 12056-12056.	0.8	0
8	Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer. <i>European Urology Oncology</i> , 2021, 4, 483-491.	2.6	39
9	Hospital-level Effects Contribute to Variations in Prostate Cancer Quality of Care. <i>European Urology Oncology</i> , 2021, 4, 494-497.	2.6	3
10	Long-term Surveillance of Patients with Complete Response Following Chemotherapy for Metastatic Nonseminomatous Germ Cell Tumor. <i>European Urology Oncology</i> , 2021, 4, 289-296.	2.6	13
11	Prostate or bone? Comparing the efficacy of image guidance surrogates for pelvis and prostate radiotherapy using accumulated delivered dose. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2021, 52, 14-21.	0.2	1
12	Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgenâ€receptorâ€targeted therapy for metastatic castrationâ€resistant prostate cancer. <i>Cancer</i> , 2021, 127, 2587-2594.	2.0	16
13	Clinical integration of machine learning for curative-intent radiation treatment of patients with prostate cancer. <i>Nature Medicine</i> , 2021, 27, 999-1005.	15.2	78
14	Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Network Open</i> , 2021, 4, e2114694.	2.8	11
15	Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castrationâ€resistant prostate cancer treated with Radiumâ€223. <i>Cancer Medicine</i> , 2021, 10, 5775-5782.	1.3	7
16	Variability in Steroid Prophylaxis for Radiation-Induced Pain Flare: Practice of Canadian Radiation Oncologists. <i>Journal of Palliative Medicine</i> , 2021, 24, 965-966.	0.6	0
17	Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. <i>European Urology</i> , 2021, 80, 374-382.	0.9	49
18	The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer. <i>Current Oncology</i> , 2021, 28, 107-114.	0.9	10

#	ARTICLE	IF	CITATIONS
19	Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Markov microsimulation model. Canadian Urological Association Journal, 2021, 16, .	0.3	3
20	Local Failure in High-grade Prostate Cancer: An Elusive but Important Outcome and Target for Clinical Trials. European Urology, 2020, 77, 209-210.	0.9	0
21	Simultaneous Vs Sequential Retroperitoneal, Thoracic and Cervical Resection of Post Chemotherapy Residual Masses in Patients With Metastatic Nonseminomatous Germ Cell Tumors of the Testis. Urology, 2020, 138, 69-76.	0.5	3
22	Current topics in radiotherapy for genitourinary cancers: Consensus statements of the Genitourinary Radiation Oncologists of Canada. Canadian Urological Association Journal, 2020, 14, E588-E593.	0.3	4
23	Clinical dilemmas in local and regional testis cancer. Canadian Urological Association Journal, 2020, 15, E58-E64.	0.3	1
24	191: Advancing A Provincial Strategic Plan: Translating Theory Into Action to Improve The Quality of Care for Patients. Radiotherapy and Oncology, 2020, 150, S81-S82.	0.3	0
25	[¹⁸ F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial. BMJ Open, 2020, 10, e035959.	0.8	8
26	A Canadian approach to the regionalization of testis cancer: A review. Canadian Urological Association Journal, 2020, 14, 346-351.	0.3	0
27	In Regard to Yerramilli et al's "Palliative Radiotherapy for Oncologic Emergencies in the Setting of COVID-19: Approaches to Balancing Risks and Benefits". Advances in Radiation Oncology, 2020, 5, 595-596.	0.6	6
28	Effects of six months of aerobic and resistance training on metabolic markers and bone mineral density in older men on androgen deprivation therapy for prostate cancer. Journal of Geriatric Oncology, 2020, 11, 1074-1077.	0.5	11
29	Controversies in the management of clinical stage 1 testis cancer. Canadian Urological Association Journal, 2020, 14, E537-E542.	0.3	4
30	The Capital Investment Strategy for Radiation therapy in Ontario: A Framework to Ensure Access to Radiation Therapy. Advances in Radiation Oncology, 2020, 5, 318-324.	0.6	5
31	Discrepancy in pathology reports upon second review of radical orchiectomy specimens for testicular germ cell tumors. Canadian Urological Association Journal, 2020, 14, 411-415.	0.3	6
32	Durable therapeutic gain despite competing mortality in long-term follow-up of a randomized hyperfractionated radiotherapy trial for locally advanced head and neck cancer. Clinical and Translational Radiation Oncology, 2020, 21, 69-76.	0.9	1
33	Tumor-targeted dose escalation for localized prostate cancer using MR-guided HDR brachytherapy (HDR) or integrated VMAT (IB-VMAT) boost: Dosimetry, toxicity and health related quality of life. Radiotherapy and Oncology, 2020, 149, 240-245.	0.3	10
34	Optimal Management of High-risk Stage I Nonseminomatous Germ Cell Tumor: Surveillance is the Preferred Option. European Urology Focus, 2019, 5, 702-703.	1.6	4
35	Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance. Journal of Clinical Oncology, 2019, 37, 1919-1926.	0.8	47
36	A Phase 1 Pilot Study of Preoperative Radiation Therapy for Prostate Cancer: Long-Term Toxicity and Oncologic Outcomes. International Journal of Radiation Oncology Biology Physics, 2019, 104, 61-66.	0.4	8

#	ARTICLE	IF	CITATIONS
37	Improving Quality of Radiation Therapy Care Across Ontario using a Community-of-Practice Approach. <i>Practical Radiation Oncology</i> , 2019, 9, e242-e248.	1.1	4
38	MRI-Guided Focal HDR Brachytherapy as Monotherapy for Prostate Cancer: Early Feasibility and Quality of Life Study. <i>Brachytherapy</i> , 2019, 18, S67.	0.2	0
39	Detection of Relapse by Low-dose Computed Tomography During Surveillance in Stage I Testicular Germ Cell Tumours. <i>European Urology Oncology</i> , 2019, 2, 437-442.	2.6	11
40	211 Developing a Strategic Plan for a Provincial Radiation Treatment Program to Advance the Quality of Care for Patients. <i>Radiotherapy and Oncology</i> , 2019, 139, S88-S89.	0.3	0
41	Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor. <i>Journal of Urology</i> , 2018, 200, 126-135.	0.2	107
42	A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma. <i>European Urology Focus</i> , 2018, 4, 995-1001.	1.6	26
43	Testicular seminoma: Scattered radiation dose to the contralateral testis in the modern era. <i>Practical Radiation Oncology</i> , 2018, 8, e57-e62.	1.1	3
44	Impact of Granulocyte-colony Stimulating Factor on Bleomycin-induced Pneumonitis in Chemotherapy-treated Germ Cell Tumors. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e193-e199.	0.9	13
45	Improving bone health in men with prostate cancer receiving androgen deprivation therapy: Results of a randomized phase 2 trial. <i>Cancer</i> , 2018, 124, 1132-1140.	2.0	11
46	Applying Radiomics to Predict Pathology of Postchemotherapy Retroperitoneal Nodal Masses in Germ Cell Tumors. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-12.	1.0	21
47	Protocol for a phase III RCT and economic analysis of two exercise delivery methods in men with PC on ADT. <i>BMC Cancer</i> , 2018, 18, 1031.	1.1	3
48	The Clinical Specialist Radiation Therapist (CSRT): A case study exploring the effectiveness of a new advanced practice role in Canada. <i>Journal of Medical Radiation Sciences</i> , 2018, 65, 86-96.	0.8	32
49	Gene expression signatures prognostic for relapse in stage I testicular germ cell tumours. <i>BJU International</i> , 2018, 122, 814-822.	1.3	8
50	Do radiation oncology outreach clinics affect the use of radiotherapy?. <i>Radiotherapy and Oncology</i> , 2018, 127, 143-149.	0.3	12
51	Regional Therapy Might Have a Role. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 511.	0.4	0
52	Improved outcomes with dose escalation in localized prostate cancer treated with precision image-guided radiotherapy. <i>Radiotherapy and Oncology</i> , 2017, 123, 459-465.	0.3	18
53	â€œI sleep better at night:â€•How peer review of radiation treatment plans indirectly improves quality of care across radiation treatment programs. <i>Practical Radiation Oncology</i> , 2017, 7, 281-288.	1.1	5
54	The effect of bowel preparation regime on interfraction rectal filling variation during image guided radiotherapy for prostate cancer. <i>Radiation Oncology</i> , 2017, 12, 50.	1.2	7

#	ARTICLE	IF	CITATIONS
55	Chemotherapy treatment decision-making experiences of older adults with cancer, their family members, oncologists and family physicians: a mixed methods study. <i>Supportive Care in Cancer</i> , 2017, 25, 879-886.	1.0	39
56	Directly Improving the Quality of Radiation Treatment Through Peer Review: A Cross-sectional Analysis of Cancer Centers Across a Provincial Cancer Program. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 521-529.	0.4	17
57	Conditional Risk of Relapse in Surveillance for Clinical Stage I Testicular Cancer. <i>European Urology</i> , 2017, 71, 120-127.	0.9	54
58	Effects of long-term androgen deprivation therapy on cognitive function over 36 months in men with prostate cancer. <i>Cancer</i> , 2017, 123, 237-244.	2.0	51
59	Long-term outcomes of a phase II trial of moderate hypofractionated image-guided intensity modulated radiotherapy (IG-IMRT) for localized prostate cancer. <i>Radiotherapy and Oncology</i> , 2017, 122, 93-98.	0.3	23
60	Optimizing computed tomography simulation wait times in a busy radiation medicine program. <i>Practical Radiation Oncology</i> , 2017, 7, e77-e83.	1.1	1
61	Recommendations for followup of stage I and II seminoma: The Princess Margaret Cancer Centre approach. <i>Canadian Urological Association Journal</i> , 2017, 12, 59-66.	0.3	12
62	Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. <i>Journal of Clinical Oncology</i> , 2017, 35, 2299-2305.	0.8	241
63	Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 1884-1890.	0.8	521
64	The association between institution at orchiectomy and outcomes on active surveillance for clinical stage I germ cell tumours. <i>Canadian Urological Association Journal</i> , 2016, 10, 204.	0.3	10
65	ReCAP: Improving the Quality of Radiation Treatment for Patients in Ontario: Increasing Peer Review Activities on a Jurisdictional Level Using a Change Management Approach. <i>Journal of Oncology Practice</i> , 2016, 12, 81-82.	2.5	20
66	Practical and clinical applications of radiation therapy. <i>Medicine</i> , 2016, 44, 15-19.	0.2	2
67	The experience of patients with early-stage testicular cancer during the transition from active treatment to follow-up surveillance. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 168.e11-168.e20.	0.8	13
68	PMH 9907: Long-term outcomes of a randomized phase 3 study of short-term bicalutamide hormone therapy and dose-escalated external-beam radiation therapy for localized prostate cancer. <i>Cancer</i> , 2016, 122, 2595-2603.	2.0	14
69	Estimating the Impact of Randomised Control Trial Results on Clinical Practice: Results from a Survey and Modelling Study of Androgen Deprivation Therapy plus Radiotherapy for Locally Advanced Prostate Cancer. <i>European Urology Focus</i> , 2016, 2, 276-283.	1.6	2
70	Lessons learned using an MRI-only workflow during high-dose-rate brachytherapy for prostate cancer. <i>Brachytherapy</i> , 2016, 15, 147-155.	0.2	28
71	The initiation of a multidisciplinary bladder cancer clinic and the uptake of neoadjuvant chemotherapy: A time-series analysis. <i>Canadian Urological Association Journal</i> , 2016, 10, 25.	0.3	17
72	Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance. <i>Cancer Medicine</i> , 2015, 4, 155-160.	1.3	129

#	ARTICLE	IF	CITATIONS
73	Long-term impact of androgen-deprivation therapy on physical function and quality of life. <i>Cancer</i> , 2015, 121, 2350-2357.	2.0	47
74	Impact of Radiotherapy When Added to Androgen-Deprivation Therapy for Locally Advanced Prostate Cancer: Long-Term Quality-of-Life Outcomes From the NCIC CTG PR3/MRC PRO7 Randomized Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2151-2157.	0.8	39
75	A phase II RCT and economic analysis of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy. <i>BMC Cancer</i> , 2015, 15, 312.	1.1	22
76	Predictors of breast radiotherapy plan modifications: Quality assurance rounds in a large cancer centre. <i>Radiotherapy and Oncology</i> , 2015, 114, 17-21.	0.3	20
77	Large Retroperitoneal Lymphadenopathy As a Predictor of Venous Thromboembolism in Patients With Disseminated Germ Cell Tumors Treated With Chemotherapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 582-587.	0.8	50
78	Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2143-2150.	0.8	213
79	Lymph Node Yield in Primary Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumors. <i>Journal of Urology</i> , 2015, 194, 386-391.	0.2	23
80	Synergistic action of image-guided radiotherapy and androgen deprivation therapy. <i>Nature Reviews Urology</i> , 2015, 12, 193-204.	1.9	41
81	Phase 2 trial of guideline-based postoperative image guided intensity modulated radiation therapy for prostate cancer: Toxicity, biochemical, and patient-reported health-related quality-of-life outcomes. <i>Practical Radiation Oncology</i> , 2015, 5, e473-e482.	1.1	24
82	Patterns of Relapse in Patients With Clinical Stage I Testicular Cancer Managed With Active Surveillance. <i>Journal of Clinical Oncology</i> , 2015, 33, 51-57.	0.8	268
83	National survey addressing the information needs of primary care physicians: Side effect management of patients on androgen deprivation therapy. <i>Canadian Urological Association Journal</i> , 2014, 8, 227.	0.3	10
84	Bisphosphonate Prescriptions in Men With Androgen Deprivation Therapy Use. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 2285.	3.8	6
85	The Prostate Cancer Risk Stratification Project: Database Construction and Risk Stratification Outcome Analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 60-69.	2.3	12
86	IMRT utilization in Ontario: qualitative deployment evaluation. <i>International Journal of Health Care Quality Assurance</i> , 2014, 27, 742-759.	0.2	0
87	Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D. <i>Osteoporosis International</i> , 2013, 24, 2571-2579.	1.3	38
88	Reply to monitoring of seminoma patients with serum markers. <i>Cancer</i> , 2013, 119, 2511-2512.	2.0	0
89	Use of Continuous Infusion Pumps During Radiation Treatment. <i>Journal of Oncology Practice</i> , 2013, 9, 107-111.	2.5	4
90	The prostate cancer risk stratification (ProCaRS) project: Recursive partitioning risk stratification analysis. <i>Radiotherapy and Oncology</i> , 2013, 109, 204-210.	0.3	34

#	ARTICLE	IF	CITATIONS
91	Contemporary Management of Stage I and II Seminoma. <i>Current Urology Reports</i> , 2013, 14, 525-533.	1.0	13
92	A survey of radiation treatment planning peer-review activities in a provincial radiation oncology programme: current practice and future directions. <i>BMJ Open</i> , 2013, 3, e003241.	0.8	36
93	Active Surveillance Is the Preferred Approach to Clinical Stage I Testicular Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3490-3493.	0.8	124
94	Changes in apparent diffusion coefficient and T ₂ relaxation during radiotherapy for prostate cancer. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 37, 909-916.	1.9	74
95	Treatment burden in stage I seminoma: a comparison of surveillance and adjuvant radiation therapy. <i>BJU International</i> , 2013, 112, 1088-1095.	1.3	40
96	Intermittent Androgen Suppression for Rising PSA Level After Radiotherapy. <i>Obstetrical and Gynecological Survey</i> , 2013, 68, 34-35.	0.2	22
97	Canadian consensus guidelines for the management of testicular germ cell cancer. <i>Canadian Urological Association Journal</i> , 2013, 4, 19.	0.3	119
98	Salvage radiotherapy following biochemical relapse after radical prostatectomy: proceedings of the Genito-Urinary Radiation Oncologists of Canada consensus meeting. <i>Canadian Urological Association Journal</i> , 2013, 2, 500.	0.3	17
99	Adjuvant radiotherapy following radical prostatectomy: Genito-Urinary Radiation Oncologists of Canada Consensus Statement. <i>Canadian Urological Association Journal</i> , 2013, 2, 95.	0.3	9
100	Treatment-related toxicity and symptom-related bother following postoperative radiotherapy for prostate cancer. <i>Canadian Urological Association Journal</i> , 2013, 4, 105.	0.3	13
101	High-intensity focused ultrasound for prostate cancer: a practice guideline. <i>Canadian Urological Association Journal</i> , 2013, 4, 232.	0.3	15
102	Pre-treatment risk stratification of prostate cancer patients: A critical review. <i>Canadian Urological Association Journal</i> , 2012, 6, 121-127.	0.3	115
103	Tumor Hypoxia Predicts Biochemical Failure following Radiotherapy for Clinically Localized Prostate Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 2108-2114.	3.2	233
104	Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy. <i>New England Journal of Medicine</i> , 2012, 367, 895-903.	13.9	428
105	Testicular cancer survivors' supportive care needs and use of online support: a cross-sectional survey. <i>Supportive Care in Cancer</i> , 2012, 20, 2737-2746.	1.0	65
106	Pathological Predictors for Site of Local Recurrence After Radiotherapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, e441-e448.	0.4	52
107	Inverse Relationship Between Biochemical Outcome and Acute Toxicity After Image-Guided Radiotherapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 608-616.	0.4	10

#	ARTICLE	IF	CITATIONS
109	The management of high-risk, locally advanced, prostate cancer radiation therapy. Canadian Urological Association Journal, 2012, 6, .	0.3	0
110	Utility of serum tumor markers during surveillance for stage I seminoma. Cancer, 2012, 118, 5245-5250.	2.0	33
111	Information needs of men on androgen deprivation therapy. BJU International, 2012, 109, 1503-1509.	1.3	20
112	The management of high-risk, locally advanced, prostate cancer radiation therapy. Canadian Urological Association Journal, 2012, 6, 393-395.	0.3	2
113	Management of Stage I Testicular Seminoma. Hematology/Oncology Clinics of North America, 2011, 25, 503-516.	0.9	7
114	Management of Localized Seminoma, Stage III: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. Urology, 2011, 78, S435-S443.	0.5	23
115	Role of Principal Component Analysis in Predicting Toxicity in Prostate Cancer Patients Treated With Hypofractionated Intensity-Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2011, 81, e415-e421.	0.4	25
116	Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet, The, 2011, 378, 2104-2111.	6.3	522
117	Radiotherapy: practical applications and clinical aspects. Medicine, 2011, 39, 705-710.	0.2	0
118	Non-“Risk-Adapted Surveillance in Clinical Stage I Nonseminomatous Germ Cell Tumors: The Princess Margaret Hospital’s Experience. European Urology, 2011, 59, 556-562.	0.9	95
119	Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer. Nature Reviews Clinical Oncology, 2011, 8, 107-113.	12.5	28
120	Stage I Seminoma: Adjuvant Treatment is Effective but is it Necessary?. Journal of the National Cancer Institute, 2011, 103, 194-196.	3.0	38
121	Stage II Seminoma and Advanced Disease. , 2011, , 197-205.		0
122	Comparison of low dose with standard dose abdominal/pelvic multidetector CT in patients with stage 1 testicular cancer under surveillance. European Radiology, 2010, 20, 1624-1630.	2.3	41
123	No Role for Routine Chest Radiography in Stage I Seminoma Surveillance. European Urology, 2010, 57, 474-479.	0.9	33
124	Sex or survival. Cancer, 2010, 116, 1909-1917.	2.0	21
125	Levels of sex hormones have limited effect on cognition in older men with or without prostate cancer. Critical Reviews in Oncology/Hematology, 2010, 73, 167-175.	2.0	19
126	Clinical Application of High-Dose, Image-Guided Intensity-Modulated Radiotherapy in High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 77, 477-483.	0.4	29

#	ARTICLE	IF	CITATIONS
127	A Cinematic Magnetic Resonance Imaging Study of Milk of Magnesia Laxative and an Antiflatulent Diet to Reduce Intrafraction Prostate Motion. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 1072-1078.	0.4	52
128	Response to "Intraoperative Radiotherapy During Radical Prostatectomy for Locally Advanced Prostate Cancer: Technical and Dosimetric Aspects" (<i>Int J Radiat Oncol Biol Phys</i> 2009; in press). <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 1277.	0.4	1
129	Healthcare costs associated with prostate cancer: estimates from a population-based study. <i>BJU International</i> , 2010, 105, 338-346.	1.3	91
130	Impact of Androgen-Deprivation Therapy on Physical Function and Quality of Life in Men With Nonmetastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 5038-5045.	0.8	157
131	Impact of Androgen-Deprivation Therapy on Cognitive Function in Men With Nonmetastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 5030-5037.	0.8	103
132	External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. <i>Lancet Oncology</i> , The, 2010, 11, 1066-1073.	5.1	830
133	Fracture Types and Risk Factors in Men With Prostate Cancer on Androgen Deprivation Therapy: A Matched Cohort Study of 19,079 Men. <i>Journal of Urology</i> , 2010, 184, 918-924.	0.2	97
134	Electronic Surveillance of Testicular Cancer: Understanding Patient Perspectives on Access to Electronic Medical Records. <i>Journal of Oncology Practice</i> , 2009, 5, 177-181.	2.5	4
135	Impact of Androgen Deprivation Therapy on Cardiovascular Disease and Diabetes. <i>Journal of Clinical Oncology</i> , 2009, 27, 3452-3458.	0.8	300
136	Major 30-day complications after radical radiotherapy. <i>Cancer</i> , 2009, 115, 293-302.	2.0	18
137	Image guided dose escalated prostate radiotherapy: still room to improve. <i>Radiation Oncology</i> , 2009, 4, 50.	1.2	57
138	Stage I seminoma: What should a practicing urologist do in 2009?. <i>International Journal of Urology</i> , 2009, 16, 544-551.	0.5	5
139	Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer. <i>BJU International</i> , 2009, 103, 753-757.	1.3	42
140	Evolving concepts in stage I seminoma. <i>BJU International</i> , 2009, 104, 1357-1361.	1.3	14
141	Validation of a Predictive Model for Survival in Metastatic Cancer Patients Attending an Outpatient Palliative Radiotherapy Clinic. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 280-287.	0.4	49
142	Recursive Partitioning Analysis of Prognostic Factors for Survival in Patients With Advanced Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 1169-1176.	0.4	17
143	Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Localization of Recurrent Prostate Cancer After External-Beam Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 425-430.	0.4	234
144	European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I. <i>European Urology</i> , 2008, 53, 478-496.	0.9	488

#	ARTICLE	IF	CITATIONS
145	European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II. European Urology, 2008, 53, 497-513.	0.9	243
146	Radiotherapy: practical applications and clinical aspects. Medicine, 2008, 36, 15-18.	0.2	3
147	Accuracy and sensitivity of finite element model-based deformable registration of the prostate. Medical Physics, 2008, 35, 4019-4025.	1.6	45
148	Hyperfractionated, accelerated radiotherapy for locally advanced head and neck cancer: Quality of life in a prospective phase I/II trial. Radiotherapy and Oncology, 2008, 87, 181-187.	0.3	40
149	A dose escalation study of hyperfractionated accelerated radiation delivered with integrated neck surgery (HARDWINS) for the management of advanced head and neck cancer. Radiotherapy and Oncology, 2008, 87, 173-180.	0.3	28
150	A phase I trial of pre-operative radiotherapy for prostate cancer: Clinical and translational studies. Radiotherapy and Oncology, 2008, 88, 53-60.	0.3	30
151	Predictive Model for Survival in Patients With Advanced Cancer. Journal of Clinical Oncology, 2008, 26, 5863-5869.	0.8	176
152	Androgen Withdrawal in Patients Reduces Prostate Cancer Hypoxia: Implications for Disease Progression and Radiation Response. Cancer Research, 2007, 67, 6022-6025.	0.4	109
153	Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 303-309.	0.8	98
154	Five year results of a randomized trial comparing hyperfractionated to conventional radiotherapy over four weeks in locally advanced head and neck cancer. Radiotherapy and Oncology, 2007, 85, 7-16.	0.3	64
155	Management of Low-Stage Testicular Seminoma. Urologic Clinics of North America, 2007, 34, 127-136.	0.8	16
156	Evidence-based guidelines for following stage 1 seminoma. Cancer, 2007, 109, 2248-2256.	2.0	73
157	A comprehensive systematic review of testicular germ cell tumor surveillance. Critical Reviews in Oncology/Hematology, 2007, 64, 182-197.	2.0	142
158	A magnetic resonance imaging study of prostate deformation relative to implanted gold fiducial markers. International Journal of Radiation Oncology Biology Physics, 2007, 67, 48-56.	0.4	160
159	Comparison of localization performance with implanted fiducial markers and cone-beam computed tomography for on-line image-guided radiotherapy of the prostate. International Journal of Radiation Oncology Biology Physics, 2007, 67, 942-953.	0.4	264
160	Patient-Assessed Late Toxicity Rates and Principal Component Analysis After Image-Guided Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2007, 68, 690-698.	0.4	53
161	Phase II Trial of Hypofractionated Image-Guided Intensity-Modulated Radiotherapy for Localized Prostate Adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1084-1089.	0.4	139
162	Anatomic Boundaries of the Clinical Target Volume (Prostate Bed) After Radical Prostatectomy. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1090-1099.	0.4	146

#	ARTICLE	IF	CITATIONS
163	Pain flare in patients with bone metastases after palliative radiotherapy—a nested randomized control trial. <i>Supportive Care in Cancer</i> , 2007, 15, 451-455.	1.0	87
164	A Randomized Phase III Study of Neoadjuvant Hormonal Therapy in Patients with Localized Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2006, 5, 235-237.	0.9	2
165	Prevention and management of osteoporosis in men receiving androgen deprivation therapy: A survey of urologists and radiation oncologists. <i>Urology</i> , 2006, 68, 126-131.	0.5	33
166	Surveillance in stage I testicular seminoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006, 24, 75-79.	0.8	21
167	Testosterone and erectile function recovery after radiotherapy and long-term androgen deprivation with luteinizing hormone-releasing hormone agonists. <i>BJU International</i> , 2006, 97, 963-968.	1.3	48
168	Compromised local control due to treatment interruptions and late treatment breaks in early glottic cancer: Population-based outcomes study supporting need for intensified treatment schedules. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 1002-1012.	0.4	69
169	Are carboplatin and radiotherapy equally effective for the adjuvant treatment of stage I seminoma?. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 18-19.	4.3	1
170	Treatment Options, Prognostic Factors and Selection of Treatment in Stage I Seminoma. <i>Oncology Research and Treatment</i> , 2006, 29, 592-598.	0.8	9
171	GU radiation oncologists consensus on bone loss from androgen deprivation. <i>Canadian Journal of Urology</i> , 2006, 13, 2962-6.	0.0	16
172	Testicular radiation for primary seminoma in a solitary testis. <i>Canadian Journal of Urology</i> , 2006, 13, 2975-7.	0.0	7
173	Postradiotherapy quality of life for head-and-neck cancer patients is independent of xerostomia. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 1403-1407.	0.4	55
174	A phase II trial of palliative radiotherapy for metastatic renal cell carcinoma. <i>Cancer</i> , 2005, 104, 1894-1900.	2.0	77
175	Randomized Trial Comparing Two Fractionation Schedules for Patients With Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 6132-6138.	0.8	331
176	Adjuvant carboplatin in stage I seminoma. <i>Lancet, The</i> , 2005, 366, 267-268.	6.3	23
177	Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy. <i>Cancer</i> , 2005, 104, 891-905.	2.0	51
178	A phase II study of localized prostate cancer treated to 75.6Gy with 3D conformal radiotherapy. <i>Radiotherapy and Oncology</i> , 2005, 76, 11-17.	0.3	47
179	SCREENING WITH PROSTATE SPECIFIC ANTIGEN AND METASTATIC PROSTATE CANCER RISK: A POPULATION BASED CASE-CONTROL STUDY. <i>Journal of Urology</i> , 2005, 174, 495-499.	0.2	41
180	A reliable coding system to define screening prostate-specific antigen tests was developed in a case-control study. <i>Journal of Clinical Epidemiology</i> , 2005, 58, 639-644.	2.4	1

#	ARTICLE	IF	CITATIONS
181	A multinational, randomized phase iii trial of iseganan hcl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. International Journal of Radiation Oncology Biology Physics, 2004, 58, 674-681.	0.4	119
182	Radiotherapy: practical applications and clinical aspects. Medicine, 2004, 32, 17-20.	0.2	0
183	Spermatocytic Seminoma: A Review. European Urology, 2004, 45, 495-498.	0.9	66
184	Stage II Testicular Seminoma: Patterns of Recurrence and Outcome of Treatment. European Urology, 2004, 45, 754-760.	0.9	115
185	The role of hemoglobin concentration in clinically localized prostate cancer treated with radical radiotherapy ± neoadjuvant androgen deprivation. International Journal of Radiation Oncology Biology Physics, 2004, 58, 53-58.	0.4	12
186	Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer. International Journal of Radiation Oncology Biology Physics, 2004, 58, 750-757.	0.4	129
187	Late toxicity following conventional radiotherapy for prostate cancer: analysis of the EORTC trial 22863. European Journal of Cancer, 2004, 40, 1674-1681.	1.3	43
188	Re: Vikram, B., The PSA conundrum. Radiother Oncol, 2004. 71(1): p. 1-2. Radiotherapy and Oncology, 2004, 73, 252-254.	0.3	1
189	Appropriate radiation volume for stage IIA/B testicular seminoma. International Journal of Radiation Oncology Biology Physics, 2003, 56, 746-748.	0.4	26
190	Recurrent prostate cancer following external beam radiotherapy. Urologic Clinics of North America, 2003, 30, 751-763.	0.8	27
191	Limitation of conventional two dimensional radiation therapy planning in nasopharyngeal carcinoma. Radiotherapy and Oncology, 2003, 68, 153-161.	0.3	45
192	Cell death in irradiated prostate epithelial cells: role of apoptotic and clonogenic cell kill. Prostate Cancer and Prostatic Diseases, 2003, 6, 73-85.	2.0	80
193	Management and Outcome Differences in Supraglottic Cancer Between Ontario, Canada, and the Surveillance, Epidemiology, and End Results Areas of the United States. Journal of Clinical Oncology, 2003, 21, 496-505.	0.8	84
194	Loss of p16 expression has prognostic significance in human nasopharyngeal carcinoma. Clinical Cancer Research, 2003, 9, 2177-84.	3.2	52
195	Prognostic Factors for Relapse in Stage I Seminoma Managed by Surveillance: A Pooled Analysis. Journal of Clinical Oncology, 2002, 20, 4448-4452.	0.8	536
196	RESPONSE TO WIECEL AND HINKELBEIN. Radiotherapy and Oncology, 2002, 62, 115-116.	0.3	0
197	Radiotherapy alone in patients with advanced nasopharyngeal cancer: comparison with an intergroup study. Radiotherapy and Oncology, 2002, 63, 269-274.	0.3	44
198	The use of conformal radiotherapy and the selection of radiation dose in T1 or T2 low or intermediate risk prostate cancer – a systematic review. Radiotherapy and Oncology, 2002, 64, 239-250.	0.3	26

#	ARTICLE	IF	CITATIONS
199	The ten-year rule revisited: accuracy of clinicians' estimates of life expectancy in patients with localized prostate cancer. <i>Urology</i> , 2002, 60, 258-263.	0.5	67
200	Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. <i>Lancet</i> , The, 2002, 360, 103-108.	6.3	1,617
201	A comparison of published head and neck stage groupings in laryngeal cancer using data from two countries. <i>Journal of Clinical Epidemiology</i> , 2002, 55, 533-544.	2.4	24
202	Acute Toxicity of Conventional Radiation Therapy for High-Risk Prostate Cancer in EORTC Trial 22863. <i>European Urology</i> , 2002, 42, 125-132.	0.9	13
203	Molecular pathology parameters in human nasopharyngeal carcinoma. <i>Cancer</i> , 2002, 94, 1997-2006.	2.0	64
204	Results of radiotherapy for primary subglottic squamous cell carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 1245-1250.	0.4	38
205	A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 54, 9-13.	0.4	93
206	A Dose-Volume Histogram Analysis of the Seminal Vesicles in Men Treated with Conformal Radiotherapy to "Prostate Alone". <i>Clinical Oncology</i> , 2002, 14, 298-302.	0.6	6
207	Controversies in the management of testicular seminoma. <i>Urologic Oncology</i> , 2002, 20, 227-233.	1.5	8
208	Clinical and biochemical outcome of conventional dose radiotherapy for localized prostate cancer. <i>Canadian Journal of Urology</i> , 2002, 9, 1444-52; discussion 1453.	0.0	13
209	Survey of radiation oncologists: practice patterns of the management of stage I seminoma of testis in Canada and a selected group in the United States. <i>Canadian Journal of Urology</i> , 2002, 9, 1479-85.	0.0	18
210	Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. <i>Radiotherapy and Oncology</i> , 2001, 59, 51-60.	0.3	154
211	Salvage radiotherapy for PSA failure after radical prostatectomy. <i>Radiotherapy and Oncology</i> , 2001, 61, 107-116.	0.3	48
212	Positioning errors and prostate motion during conformal prostate radiotherapy using on-line isocentre set-up verification and implanted prostate markers. <i>Radiotherapy and Oncology</i> , 2001, 61, 127-133.	0.3	189
213	Glottic cancer in Ontario, Canada and the SEER areas of the United States. <i>Journal of Clinical Epidemiology</i> , 2001, 54, 301-315.	2.4	53
214	Surveillance for stage I testicular seminoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2001, 6, 139-143.	0.8	18
215	The impact of irregularly rising prostate-specific antigen and "impending failure" on the apparent outcome of localized prostate cancer following radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 49, 957-963.	0.4	11
216	Portal imaging for evaluation of daily on-line setup errors and off-line organ motion during conformal irradiation of carcinoma of the prostate. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 49, 869-884.	0.4	153

#	ARTICLE	IF	CITATIONS
217	Carcinoma-in-situ of the glottic larynx: results of treatment with radiation therapy. International Journal of Radiation Oncology Biology Physics, 2001, 49, 1235-1238.	0.4	42
218	Neoadjuvant hormonal therapy in carcinoma of the prostate. BJU International, 2001, 83, 438-448.	1.3	30
219	Does age influence the behaviour of localized prostate cancer?. BJU International, 2001, 87, 629-637.	1.3	30
220	A comparison of published head and neck stage groupings in carcinomas of the tonsillar region. Cancer, 2001, 92, 1484-1494.	2.0	54
221	Impact of Noninvasive Imaging on Increased Incidental Detection of Renal Cell Carcinoma. European Urology, 2000, 37, 521-527.	0.9	111
222	Errors from field placement and organ motion during conformal radiotherapy for prostate cancer. Journal of Radiotherapy in Practice, 2000, 2, 65-73.	0.2	0
223	Urethral carcinoma in women: results of treatment with primary radiotherapy. Radiotherapy and Oncology, 2000, 56, 29-35.	0.3	62
224	Carcinoma of the maxillary antrum: a retrospective analysis of 110 cases. Radiotherapy and Oncology, 2000, 57, 167-173.	0.3	82
225	Management of testicular seminoma. , 1999, 17, 240-249.		21
226	PROGRESSION DETECTION OF STAGE I NONSEMINOMATOUS TESTIS CANCER ON SURVEILLANCE: IMPLICATIONS FOR THE FOLLOWUP PROTOCOL. Journal of Urology, 1999, 161, 472-476.	0.2	77
227	T1/T2 Glottic Cancer Managed by External Beam Radiotherapy: The Influence of Pretreatment Hemoglobin on Local Control. International Journal of Radiation Oncology Biology Physics, 1998, 41, 347-353.	0.4	169
228	Ethmoid Sinus Cancer: Twenty-nine Cases Managed With Primary Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 1998, 41, 361-369.	0.4	91
229	The management of locally advanced prostate cancer. Urologic Oncology: Seminars and Original Investigations, 1998, 4, 3-12.	0.8	22
230	SURVEILLANCE FOR STAGE I TESTICULAR SEMINOMA. Urologic Clinics of North America, 1998, 25, 425-433.	0.8	41
231	Magnetic resonance imaging (MRI) for localization of the prostatic apex: comparison to computed tomography (CT) and urethrography. Radiotherapy and Oncology, 1998, 47, 277-284.	0.3	117
232	Management of stage II seminoma.. Journal of Clinical Oncology, 1998, 16, 290-294.	0.8	88
233	Improvement in total positioning error for lateral prostatic fields using a soft immobilization device. Radiotherapy and Oncology, 1997, 44, 265-270.	0.3	34
234	Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin. New England Journal of Medicine, 1997, 337, 295-300.	13.9	1,455

#	ARTICLE	IF	CITATIONS
235	Resource implications of palliative chemotherapy for ovarian cancer.. Journal of Clinical Oncology, 1997, 15, 1000-1007.	0.8	46
236	2108 Urethral carcinoma in women: Results of treatment with primary radiotherapy. International Journal of Radiation Oncology Biology Physics, 1997, 39, 294.	0.4	1
237	Regarding Chao et al IJROBP 33(4):831-835; 1995. International Journal of Radiation Oncology Biology Physics, 1997, 38, 673-674.	0.4	2
238	Stage I testicular seminoma: results of adjuvant irradiation and surveillance.. Journal of Clinical Oncology, 1995, 13, 2255-2262.	0.8	173
239	Benign parotid adenomas: A review of the princess margaret hospital experience. Head and Neck, 1995, 17, 177-183.	0.9	42
240	Role of epstein-barr virus in fine-needle aspirates of metastatic neck nodes in the diagnosis of nasopharyngeal carcinoma. Head and Neck, 1995, 17, 487-493.	0.9	45
241	Outcome following radiotherapy in verrucous carcinoma of the larynx. International Journal of Radiation Oncology Biology Physics, 1995, 32, 611-617.	0.4	36
242	Radiation treatment of cervical lymph node metastases from an unknown primary: an analysis of outcome by treatment volume and other prognostic factors. Radiotherapy and Oncology, 1995, 35, 206-211.	0.3	95
243	The influence of transurethral resection of prostate on prognosis of patients with adenocarcinoma of the prostate treated by radical radiotherapy. Radiotherapy and Oncology, 1994, 31, 41-50.	0.3	10
244	Carcinoma of the prostate: Results of radical radiotherapy (1970-1985). International Journal of Radiation Oncology Biology Physics, 1993, 26, 203-210.	0.4	72
245	Results of a policy of surveillance in stage I testicular seminoma. International Journal of Radiation Oncology Biology Physics, 1993, 27, 11-15.	0.4	72
246	Is Steroid Receptor Data Useful in Patients with Metastatic Breast Cancer?. American Journal of the Medical Sciences, 1992, 304, 9-13.	0.4	2
247	Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis.. Journal of Clinical Oncology, 1992, 10, 890-895.	0.8	764
248	A management approach to incompletely excised basal cell carcinomas of skin. International Journal of Radiation Oncology Biology Physics, 1991, 20, 423-428.	0.4	95
249	The Use of a Markov Process to Simulate and Assess Follow-up Policies for Patients with Malignant Disease. Medical Decision Making, 1991, 11, 131-139.	1.2	19
250	Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer.. Journal of Clinical Oncology, 1990, 8, 1301-1309.	0.8	215
251	RECPAM analysis of prognostic factors in patients with Stage III breast cancer. Breast Cancer Research and Treatment, 1990, 16, 231-242.	1.1	14
252	The costs of cancer therapy. European Journal of Cancer & Clinical Oncology, 1990, 26, 223-225.	0.9	7

#	ARTICLE	IF	CITATIONS
253	Eliciting preferences for alternative drug therapies in oncology: Influence of treatment outcome description, elicitation technique and treatment experience on preferences. <i>Journal of Chronic Diseases</i> , 1987, 40, 811-818.	1.3	137
254	Chemotherapy treated hodgkins disease " A fifteen year review. <i>Irish Journal of Medical Science</i> , 1986, 155, 300-307.	0.8	1
255	Renal glomerulopathies associated with Hodgkin's disease. <i>Cancer</i> , 1985, 56, 874-875.	2.0	17
256	Alleviation of chemotherapy induced emesis by oral lorazepam and domperidone. <i>Irish Journal of Medical Science</i> , 1983, 152, 336-338.	0.8	2